I hereb carrier that the correspondence is being deposited with the U.S. Postal Service with the U.S. P

Docket No.: CIMA 3.0-030 CONT CONT (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Pather et al.

Application No.: 09/661,693 Group Art Unit: 1616

Filed: September 14, 2000 Examiner: M. Lamm

For: SUBLINGUAL BUCCAL EFFERVESCENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each foreign and journal reference is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

The references identified in this IDS have not been cited in corresponding foreign applications, but have been cited in other patent applications owned by the assignee of the subject application, which other applications are directed to related technology.

07/06/2005 RFEKADU1 00000020 121095 09661693 03 FC:1806 180.00 DA Application No.: 09/661,693 Docket No.: CIMA 3.0-030 CONT CONT

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: June 28, 2005

Respectfully submitted,

Harvey L. Cohen

Registration No.: 28,365 LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-458\

I hereby BAOS at this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1460 on the date shown below.

Dated: June 28, 2005 Signature: ((Harvey L: Coden)

Docket No.: CIMA 3.0-030 CONT CONT (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Pather et al.

Application No.: 09/661,693

Group Art Unit: 1616

Filed: September 14, 2000

Examiner: M. Lamm

For: SUBLINGUAL BUCCAL EFFERVESCENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)

Dear Sir:

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge deposit account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our deposit account No. 12-1095.

Dated: June 28, 2005

Respectfully symmitted,

Harvey L. Colen

Registration No.: 28,365 LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-453\

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
tk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Application Number 09/661,693-Conf. #2096 INFORMATION DISCLOSURE Filing Date September 14, 2000 STATEMENT BY APPLICANT First Named Inventor S. Indiran Pather Art Unit 1616 (Use as many sheets as necessary) M. Lamm Examiner Name Sheet 1 of 2 Attorney Docket Number CIMA 3.0-030 CONT CONT

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-1,262,888	04/1918	Preble, W.P. et al.	
	AB	US-3,577,490	05/1971	Welsh, T. L. et al.	
	AC	US-3,888,976	06/1975	Mlkvy et al.	
	AD	US-3,961,041	06/1976	Nishimura et al.	
	AE	US-4,147,768	04/1979	Schaffer et al.	
	AF	US-4,187,286	02/1980	MARCUS, B.J.	
	AG	US-4,289,751	09/1981	Windheuser	
	AH	US-4,503,031	03/1985	Glassman	
	ΑI	US-4,599,342	07/1986	LAHANN, THOMAS R.	
	AJ	US-4,671,953	06/1987	STANLEY ET AL.	
	AK	US-4,756,710	07-12-1988	Bondi et al.	
	AL	US-5,073,374	12/1991	MCCARTY, JOHN A.	
	АМ	US-5,468,504	11/1995	Schaeffer, Alain E. E.	
	AN	US-5,503,846	04-02-1996	Wehling et al.	
	AO	US-5,559,096	09/1996	Edwards et al.	
	AP	US-5,624,687	04-29-1997	Yano et al.	
	AQ	US-5,626,866	05-06-1997	Ebert et al.	
	AR	US-5,646,151	07/1997	Kruse et al.	
	AS	US-5,853,748	12-29-1998	New	
	AT	US-5,900,252	05-04-1999	Calanchi et al.	
	AU	US-5,952,004	09-14-1999	Rudnic et al.	
	AV	US-6,034,085	03-07-2000	Joshi et al.	
	AW	US-6,068,853	05-30-2000	Giannos et al.	
	AX	US-6,129,906	10/2000	Steventon	
	AY	US-6,200,604	03-13-2001	Pather et al.	
	AZ	US-6,316,027-B1	11-13-2001	Clarke, Anthony et al.	
	AA1	US-6,350,470-B1	02/2002	Pather et al.	
	AB1	US-6,391,335	05-21-2002	Pather et al.	
	AC1	US-6,488,961	12/2002	ROBINSON ET AL.	
	AD1	US-6,509,036	01-21-2003	Pather et al.	
	AE1	US-6,576,250-B1	06/2003	Pather er al.	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	ВА	EP-0 197 504-A1	10-15-1986	Bondi et al.		М
	ВВ	EP-0 354 973-B2	02-21-1990	Paradissis		
	ВС	EP-0361680-A2	04/1990	MICHELL		
	BD	GB-2307857-A	06/1997	LESLIE ET AL.		
	BE	WO-95/27482-A1	10/1995	FREEMAN ET AL.		
	BF	WO-95/34291-A1	12-21-1995	JENSEN LINE NOERGAARD		
	BG	WO-97/17067-A1	05-15-1997	Somerset Pharmaceuticals		
	<u> </u>			Inc.		

Examiner	Date
Signature	Considered
5700.40	



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	Substitute for form 1449A/B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)		Complete if Known		
				Application Number	09/661,693-Conf. #2096
11	NFORMATION	I DI	SCLOSURE	Filing Date	September 14, 2000
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	S. Indiran Pather
				Art Unit	1616
	(Use as many sh	eets as	s necessary)	Examiner Name	M. Lamm
Sheet	2	of	2	Attorney Docket Number	CIMA 3.0-030 CONT CONT

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> <sup>2</sup>
	CA	AMIGHI, K.; TIMMERMANS, J.; PUIGDEVALL, J.; BALTES, E.; MOËS, A J.; Peroral Sustained-Release Film-Coated Pellets as a Means to Overcome Physicochemical and Biological Drug-Related Problems. I. In Vitro Development and Evaluation, Drug Development and Industrial Pharmacy, 1998, pp. 509-515, vol. 24, no. 6.	
	СВ	BERKO, S.; REGDON JUN, G.; ERÖS, I.; Influence of pH Change on Drug Release from Rectal Suppositories, Die Pharmazie, April 2000, p.324, Vol. 55., Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn.	
	C	GIANNOS, S.A.; DINH, S.M.; BERNER, B.; Temporally Controlled Drug Delivery Systems: Coupling of pH Oscillators with Membrane Diffusion, Journal of Pharmaceutical Sciences, May 1995, pp. 539-543, Vol. 84, No. 5.	
	CD	Nishimura et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa VI: Formulation of Effervescent Enteric-Coated Tablets" J. Pharm. Sci. 73(7):942-46 (1984).	
	CE	RANADE, V.V.; Drug Delivery Systems Part 5B. Oral Drug Delivery, The Journal of Clinical Pharmacology, Feb. 1991, pp. 98-115, Vol. 31.	
	CF	Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients" J. Pharm. Sci. 69(3):261-65 (1980).	
	CG	Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa III: Influence of Dose on Pharmacokinetic Behavior of Levodopa in Dogs and Parkinsonian Patients" J. Pharm. Sci. 69(12):1374-78 (1980).	
	СН	Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa V: Absorption and Metabolism of Levodopa in Intestinal Segments of Dogs" J. Pharm. Sci. 70(10):1157-60 (1981).	
	CI	Sasahara et al., "Dosage Form Design for Improvement of Bioavailibity of Levodopa IV: Possible Causes of Low Bioavailability of Oral Levodopa in Dogs" J. Pharm. Sci. 70(7):730-33 (1981).	
	CJ	SORASUCHART, W.; WARDROP, J.; AYERS, J.; Drug Release from Spray Layered and Coated Drug-Containing Beads: Effects of pH and Comparison of Different Dissolution Methods, Drug Development and Industrial Pharmacy, 1999, pp. 1093-1098, Vol. 25, No. 10	_
	CK	STREUBEL, A.; SIEPMANN, J.; DASHEVSKY, A.; BODMEIER, R.; pH-Independent Release of a Weakly Basic Drug from Water-Insoluble and -Soluble Matrix Tablets, Journal of Controlled Release, 2000, pp. 101-110, Vol. 67.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.